Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-3792
- Development stage
- Phase 1
- Lead developer
- Suzhou Suncadia Biopharmaceutical
- Modality
- Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Parenteral, Injection (likely Intravenous Or Subcutaneous; Specific Route Not Detailed)
01
Overview
SHR-3792 is an investigational antineoplastic drug being developed for the treatment of advanced solid tumors. It is classified as a biological product and represents a new molecular entity. The precise mechanism of action has not been disclosed publicly, but preclinical studies have demonstrated notable anti-tumor activity in animal models. Clinical development is ongoing, with phase 1 trials initiated to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced or metastatic solid tumors. The drug was independently developed by Suzhou Suncadia Biopharmaceuticals and is also associated with Shanghai Hengrui Pharmaceutical[1][2][9].
- Other names
- SHR 3792SHR3792SHR-3792
Beyond the preview
Go deeper on SHR-3792.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-3792.